December 17, 2024

Food Recall Trends: Listeria, Salmonella, and E. coli Risks

Explore key insights from a 2-decade analysis of US food recalls, revealing alarming trends in foodborne illness outbreaks caused by Listeria, Salmonella, and E. coli, and the need for improved food safety measures.

Conexiant

December 12, 2024

Phase 3 Data: Nemolizumab for Prurigo Nodularis Relief

A recent study published in JAMA Dermatology revealed the significant efficacy of nemolizumab in reducing pruritus and skin lesions in patients with moderate to severe prurigo nodularis.

Conexiant

December 11, 2024

Combo Induces HBsAg Loss in HBV

A recent study found that a combination therapy in chronic hepatitis B patients with virologic suppression showed promising results in achieving HBsAg loss, but emphasized the need for longer follow-up to assess durability and potential side effects.

Conexiant

December 11, 2024

Pro-inflammatory Diet May Weaken Women's Bones

Study finds that hypertensive women consuming pro-inflammatory diets are at an increased risk of osteopenia due to lower lumbar vertebrae bone mineral density.

Conexiant

December 11, 2024

Blinatumomab Enhances Disease-Free Survival in B-Cell ALL: Study

A recent study published in The New England Journal of Medicine found that adding blinatumomab to standard chemotherapy significantly improved disease-free survival in children with standard-risk B-cell acute lymphoblastic leukemia, reducing relapse rates and especially decreasing bone marrow relapse.

Conexiant

December 10, 2024

Biomarkers in Familial Mediterranean Fever: Therapy Insights

A recent study on familial Mediterranean fever revealed that nearly 56% of heterozygous patients who stopped colchicine therapy sustained remission with lower levels of specific biomarkers, highlighting the potential of personalized treatment for FMF patients.

Conexiant

December 09, 2024

Do SGLT2i, GLP-1 RAs Cut Pneumonia, Sepsis Risk?

In the largest real-world study to date, GLP-1 receptor agonists reduced pneumonia risk by 40% in type 2 diabetes patients.

Conexiant

December 09, 2024

Reduced Infection Rates with Long-Term Dupilumab in Kids

A recent study reveals that dupilumab can reduce infection rates in young children with moderate-to-severe atopic dermatitis, offering potential long-term benefits for this patient population.

Conexiant

December 09, 2024

UV Radiation, Virus Key Drivers of Merkel Cell Carcinoma Cases

A recent study in JAMA Dermatology reveals that over 65% of Merkel cell carcinoma cases in the US may be attributed to ultraviolet radiation exposure, while 63.8% may be linked to the Merkel cell polyomavirus.

Conexiant